INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Corporate insider
GP

Greenleaf Peter

DirectorCIK 0001363683

EDGAR filingsOpen in network
Disclosed transactions6
Buys / sells0 / 5
Max Insider Score20
Connections2with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
GP
Greenleaf PeterDirector
ALTAltimmune, Inc.
Grant or award
A—
160.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Altimmune, Inc.Director · Nov 4, 2026
  • Insider ofevidence
    Pelthos Therapeutics Inc.Director · Apr 6, 2026
11
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL
$17K
797 sh
Oct 2, 2026
Oct 6, 2026
traded Oct 2, 2026
+4d
SEC FORM 4

Evidence

17
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$19K
712 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

17
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$2,318
85 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

20
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$8,616
420 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence

20
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$8,053
377 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence